These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 9614626)

  • 1. International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
    Bloomgarden ZT
    Diabetes Care; 1998 Jun; 21(6):1024-6. PubMed ID: 9614626
    [No Abstract]   [Full Text] [Related]  

  • 2. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.
    Gavin LA; Barth J; Arnold D; Shaw R
    Endocr Pract; 2000; 6(4):305-10. PubMed ID: 11242607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
    Hershon KS; Hershon PM
    Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
    Scheen AJ; Lefèbvre PJ
    Diabetes Care; 1999 Sep; 22(9):1568-77. PubMed ID: 10480527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
    Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
    Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
    Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
    [No Abstract]   [Full Text] [Related]  

  • 7. Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes.
    Garber AJ
    Diabetes Obes Metab; 2000 Jun; 2(3):139-47. PubMed ID: 11220549
    [No Abstract]   [Full Text] [Related]  

  • 8. Increase of lipoprotein (a) with troglitazone.
    Matsumoto K; Miyake S; Yano M; Ueki Y; Tominaga Y
    Lancet; 1997 Dec; 350(9093):1748-9. PubMed ID: 9413470
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of insulin secretagogues in the treatment of type 2 diabetes.
    Luna B; Hughes AT; Feinglos MN
    Prim Care; 1999 Dec; 26(4):895-915. PubMed ID: 10523467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of insulin alone and in combination with oral agents in type 2 diabetes.
    Buse JB
    Prim Care; 1999 Dec; 26(4):931-50. PubMed ID: 10523468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
    Ohmura E; Hosaka D; Imai Y; Kawazu S
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
    [No Abstract]   [Full Text] [Related]  

  • 12. [Combination therapy with biguanides].
    Sakura H
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():724-8. PubMed ID: 12430309
    [No Abstract]   [Full Text] [Related]  

  • 13. The Diabetes Prevention Program.
    Muniyappa R; El-Atat F; Aneja A; McFarlane SI
    Curr Diab Rep; 2003 Jun; 3(3):221-2. PubMed ID: 12762969
    [No Abstract]   [Full Text] [Related]  

  • 14. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
    Blonde L; Sandberg MI; Guthrie RD
    Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
    [No Abstract]   [Full Text] [Related]  

  • 15. [Troglitazone].
    Yamanouchi T
    Nihon Rinsho; 2000 Feb; 58(2):389-94. PubMed ID: 10707563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
    Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
    N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.
    Caro JJ; Klittich WS; Raggio G; Kavanagh PL; O'Brien JA; Shomphe LA; Flegel KM; Copley-Merriman C; Sigler C
    Clin Ther; 2000 Jan; 22(1):116-27. PubMed ID: 10688395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A miracle of salamization: positive divided by two equals negative.
    Iwamoto Y
    Diabet Med; 1997 Nov; 14(11):994. PubMed ID: 9400931
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
    Bressler R; Johnson DG
    Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
    Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.